Outcomes in patients with mixed cardiogenic and vasoplegic shock
Official title: Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock: a French Multicenter Cohort
Run by Centre Hospitalier Universitaire, Amiens · NCT07354568 · Data updated 2026-11-12
This registry will try to describe outcomes and risk factors in adults admitted with cardiogenic shock who also have inappropriate vasodilation (mixed cardiogenic‑vasoplegic shock).
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2500 (estimated) |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens, Somme) |
| Status | Recruiting |
| Started | October 20, 2025 |
| Main results expected | January 1, 2027 |
| Study ends | June 1, 2027 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT07354568 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18) admitted to the ICU with cardiogenic shock at SCAI stage C or higher who have documented vasopressor dosing and outcome data and do not oppose use of their data.
✕Probably not a fit
Patients with excluded non‑cardiogenic shock causes (for example anaphylaxis, massive hemorrhage, major trauma, severe pancreatitis, fulminant hepatic failure, or neurogenic shock), pregnant women, those under legal protection, or those missing key vasopressor or outcome data are unlikely to benefit from the registry's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This retrospective multicenter observational registry collects routine clinical, laboratory, and invasive hemodynamic data from adults admitted to ICUs for cardiogenic shock with or without vasoplegia. The primary aim is to describe mortality and organ failure rates, and secondary analyses will identify determinants of adverse outcomes including vasopressor requirements and use of mechanical circulatory support such as VA‑ECMO. Inclusion requires adults (≥18) with cardiogenic shock at least SCAI stage C and available vasopressor and outcome data, while non‑eligible shock etiologies and pregnant patients are excluded. Data are contributed by participating French university hospitals (Amiens, Dijon, Rouen) and analyzed retrospectively to characterize the epidemiology and prognosis of the mixed phenotype.
Why it matters
Potential benefit: If successful, the registry could help clinicians better predict which patients are at highest risk and inform decisions about vasopressors and mechanical support.
How similar studies have gone: Other observational registries have characterized cardiogenic shock outcomes and experience with VA‑ECMO and vasopressors, but focusing specifically on the mixed cardiogenic‑vasoplegic phenotype is relatively novel and less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (\>18 years old) * Admitted to an intensive care unit for cardiogenic shock, at least SCAI stage C * No opposition to data use Exclusion Criteria: * Missing key data, particularly regarding vasopressor doses and outcomes. * Pregnant women * Non-eligible shock etiologies, including but not limited to: * Anaphylactic shock, * Isolated hemorrhagic shock, * Severe burns or major trauma, * Severe acute pancreatitis, * Fulminant hepatic failure, * Neurogenic shock. * Adult under legal protection (guardianship, curatorship, or judicial protection).
Where it's running
-
CHU Amiens Picardie
Amiens, Somme, France Recruiting
Study contacts
- Study coordinator: Christophe Beyls, MD, PhD
- Email: beyls.christophe@chu-amiens.fr
- Phone: + 33 322087866
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Optimizing Impella 5.5 Outcomes With Advanced Data Science
This study tests whether real-world data from Impella 5.5 patients with cardiogenic shock can help predict heart recovery and prevent complications, using advanced data science.
-
Cardiogenic Shock Outcomes Registry (COR-SHOCK): how patients fare over time
This observational registry tests how outcomes and management of cardiogenic shock have changed over the years in adults receiving routine care.
-
Adjunctive Fludrocortisone in Septic Shock on Hydrocortisone
In septic shock, this trial tests whether adding fludrocortisone (50 mcg or 100 mcg daily) to hydrocortisone improves survival and recovery compared with placebo.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
-
Risk of malignant arrhythmias after acute coronary syndrome
This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.